Just to make it also clear they have Russian approval. Statistically from what I remember reading there are 10 million liver degenerative cases in Russia at present with a million or so being added annually. Do the mathematics. Numerous Russian hospitals have already indicated that they wish to use Ropren. It wouldn't even hurt the Company if Ropren wasn't available here! The Russian side alone is enough to catapult the share price well above current levels. The Russians believe in the product which is substantially cheaper than current products with none of the side effects. SLA from what was relayed at the meeting and what was contained within the presentation appear to be targeting European interests anyway at this stage. Once they get the European funds on board etc watch out!
- Forums
- ASX - By Stock
- SLA
- ropren facts
ropren facts, page-17
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online